FDA Drug Approval Summary: Nelarabine (Arranon®) for the Treatment of T-Cell Lymphoblastic Leukemia/Lymphoma
Open Access
- 1 June 2008
- journal article
- Published by Oxford University Press (OUP) in The Oncologist
- Vol. 13 (6), 709-714
- https://doi.org/10.1634/theoncologist.2006-0017
Abstract
Learning Objectives: After completing this course, the reader will be able to: Add nelarabine (Arranon®) to the armamentarium of drugs for T-cell lymphoblastic leukemia/lymphoma.Identify patients that are eligible for nelarabine therapy.Identify the nelarabine dose-limiting toxicity.Describe the FDA criteria for accelerated approval. CME This article is available for continuing medical education credit at CME.TheOncologist.com Purpose.: To describe the clinical trials leading to U.S. Food and Drug Administration (FDA) approval of nelarabine (Arranon®), a new purine analogue, for the treatment of patients with T-cell acute lymphoblastic leukemia (T-ALL) and T-cell lymphoblastic lymphoma (T-LBL) whose disease has not responded to or has relapsed following treatment with at least two chemotherapy regimens. Experimental Design.: Two phase II trials, one conducted in pediatric patients and the other in adult patients, were reviewed. Patients were in their first or subsequent relapse and/or were refractory to first-line therapy. The dose and schedule of i.v. nelarabine in the pediatric and adult studies were 650 mg/m2 per day daily for 5 days and 1,500 mg/m2 i.v. on days 1, 3, and 5, respectively. Treatments were repeated every 21 days. Study endpoints were the rates of complete response (CR) and CR with incomplete hematologic or bone marrow recovery (CR*). Results.: The pediatric efficacy population consisted of 39 patients who had relapsed after, or had been refractory to, two or more induction regimens. CR to nelarabine treatment was observed in five patients (13%) and CR+CR* was observed in nine patients (23%). The adult efficacy population consisted of 28 patients. CR to nelarabine treatment was observed in five patients (18%) and CR+CR* was observed in six patients (21%). Neurologic toxicity was dose limiting for both pediatric and adult patients. Other severe toxicities included hematologic, hepatic, and metabolic laboratory abnormalities in pediatric patients and gastrointestinal and pulmonary toxicities in adults. Conclusions.: On October 28, 2005, the FDA granted accelerated approval for nelarabine for treatment of patients with relapsed or refractory T-ALL/T-LBL after at least two prior regimens. This use is based on the induction of CR. The applicant will conduct postmarketing clinical trials to demonstrate clinical benefit, for example, survival prolongation.Keywords
This publication has 7 references indexed in Scilit:
- Long-Term Outcome in Children With Relapsed ALL by Risk-Stratified Salvage Therapy: Results of Trial Acute Lymphoblastic Leukemia-Relapse Study of the Berlin-Frankfurt-Münster Group 87Journal of Clinical Oncology, 2005
- Phase II Study of Nelarabine (compound 506U78) in Children and Young Adults With Refractory T-Cell Malignancies: A Report From the Children’s Oncology GroupJournal of Clinical Oncology, 2005
- Phase I Study of 506U78 Administered on a Consecutive 5-Day Schedule in Children and Adults With Refractory Hematologic MalignanciesJournal of Clinical Oncology, 2005
- Long‐term follow‐up of relapsed childhood acute lymphoblastic leukaemiaBritish Journal of Haematology, 2003
- End Points and United States Food and Drug Administration Approval of Oncology DrugsJournal of Clinical Oncology, 2003
- Pharmacokinetics of Nelarabine and 9-Beta-d-Arabinofuranosyl Guanine in Pediatric and Adult Patients During a Phase I Study of Nelarabine for the Treatment of Refractory Hematologic MalignanciesJournal of Clinical Oncology, 2000
- Biochemical basis for the enhanced toxicity of deoxyribonucleosides toward malignant human T cell lines.Proceedings of the National Academy of Sciences of the United States of America, 1979